Understanding why targeted breast cancer therapies eventually stop working may be the single most consequential challenge in oncology today. Despite remarkable treatment advances, acquired resistance continues to limit long-term survival gains for millions of patients globally — and a new integrative framework attempts to systematically map why that happens across the full spectrum of breast cancer subtypes.

Published in Critical Reviews in Oncology/Hematology, this comprehensive review proposes a four-layer network topology model to explain how tumors evade precision therapies. The first layer involves canonical pathway reactivation — tumors finding workarounds within the same signaling highways being blocked. The second captures receptor tyrosine kinase (RTK) reprogramming, where alternative surface receptors compensate for those being inhibited. The third introduces non-coding RNA regulatory circuits as underappreciated mediators of treatment failure. The fourth layer links epigenetic plasticity with dynamic co-evolution of the tumor microenvironment (TME), a process in which non-cancerous cells surrounding the tumor actively participate in enabling resistance. The review applies this model across three major clinical contexts: HER2-targeted therapy, including the newly expanded HER2-low and HER2-ultralow populations now addressable by antibody-drug conjugates (ADCs); CDK4/6 inhibitors in hormone receptor-positive disease; and immune checkpoint blockade in triple-negative breast cancer.

What distinguishes this framework is its explicit three-tier evidence stratification — separating clinically actionable mechanisms from plausibly translational and merely exploratory ones. This is methodologically significant: resistance biology literature has long suffered from conflation of compelling preclinical results with validated clinical biomarkers. For health-conscious adults tracking oncology progress, the practical implication is sobering but clarifying — most resistance mechanisms currently identified remain exploratory, meaning treatment personalization based on resistance profiling is still largely aspirational. The inclusion of liquid biopsy as a future direction suggests real-time resistance monitoring may eventually translate these mechanisms into clinical decision-making. This is a confirmatory and synthesizing contribution rather than a paradigm shift, but its structured evidence hierarchy gives clinicians and researchers a more rigorous scaffold than previous narrative reviews.